Wells Fargo raised the firm’s price target on Rapt Therapeutics (RAPT) to $6 from $4 and keeps an Overweight rating on the shares. With the in-license of a food allergy/CSU drug with a validated target and derisking Phase 1 pharmacokinetic-pharmacodynamic data supporting long dosing intervals, the firm sees significant upside for Rapt heading into proof-of-concept readouts starting in the second half of 2025.
Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RAPT:
- RAPT Therapeutics Partners with Jemincare and Secures Funding
- RAPT Therapeutics prices 100M shares at 85c in private placement
- Rapt Therapeutics, Jemincare enter exclusive license agreement for JBY1904
- RAPT Therapeutics Reprices Underwater Employee Stock Options
- Biotech Alert: Searches spiking for these stocks today